Anixa Biosciences, Inc. · NASDAQ:ANIX
Anixa Biosciences — Shareholder Meeting (March 2025)
38 slides from Anixa Biosciences's shareholder meeting presentation, Mar 21, 2025
Slide 1: Shareholder Meeting Presentation
Aanixa BIOSCIENCES NASDAQ:ANIX March 20, 2025 Shareholder Meeting Presentation Dr. Amit Kumar Chairman and CEO
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences’ current
Slide 3: Anixa Snapshot
Anixa Snapshot Clinical-stage company developing first-in-class products to treat & prevent cancer Robust Pipeline $$$ Strong Balance Sheet lal Strong Clinical Data all Clean Capital Table Aanixa we fa ES ©) Key Significant TAM Partnerships Opportunity Strong Consistent Capital Efficient Insider Buy
Slide 4: Capital Efficient Business Model
Capital Efficient Business Model NASDAQ:ANIX $17 Cash and short-term investments as of January 31, 2025 ~$5 2 7M Approximate annual cash burn since 2017 32M Common shares outstanding as of January 31, 2025 OS No debt No warrants, no preferred stock = Develop programs with partners v Leverage existin
Slide 5: Clinical Programs & Development Partnerships
Clinical Programs & Development Partnerships THERAPEUTIC MECHANISM. GEOGRAPHIC UPCOMING. AREA oF ACTION INDICATION RIGHTS MILESTONES CARINERS CAR-T na) Reiocte cata MOFFITT) Oncology f Global Phase 1 releases Therapeutic Other Solid (enrollment based) WISTAR Tumors INO , Additional Phase Vaccine Onc
Slide 6: CAR-T Program
CAR-T Program Ovarian Cancer Therapy
Slide 7: CAR-T Procedure- Chimeric Antigen Receptor T cell
CAR-T Procedure- Chimeric Antigen Receptor T cell s ad < o <
Slide 8: CAR-T Technology
« Ed < 6 < CAR-T Technology Background & opportunity Chimeric Antigen Receptor T cell Cell cancers Our Unique Approach Durable responses (50-80% of patients) + Anixa’s novel tech has three unique attributes: = Multi-billion-dollar valuations and big pharma deals © Novartis - First approved product b
Slide 9: Anixa's Unique & Targeted CAR-T Approach for Solid Tumors
Anixa’s Unique & Targeted CER-T Approach for Solid Tumors Exclusive worldwide license from The Wistar Institute Anixa's CAR-T Program for Ovarian Cancer Other CAR-T Programs Follicle Stimulating Hormone Receptor ("FSHR")- Novartis, JUNO, KITE and others working on B-Cell mediated CAR-T Technology ca
Slide 10: FSHR Only Expressed in Ovaries, Testes and Tumor Blood Vessels
exiuev FSHR ONLY Expressed in Ovaries, Testes and Tumor Blood Vessels oWad Him sisal ee yseaig usewoig eunseqUy Ilewg smuein eUselL PUEID PIOJAYL snk, ueeidg e1osnw 1eIele4S purl Aenies Only in Fetal Thymus = res [e194 jou ue, unjjeqaie9 uleig puri leueipy ° B 8 8 3 s o|sse1dxg YNYW YHSJ SAYO}eg 0.0
Slide 11: Our FSHR-Mediated CAR-T Technology- Dual Mechanism of Action
Our FSHR-Mediated CAR-T Technology- Dual Mechanism of Action g [= o ; Angiogenesis = Many tumors have blood vessels where FSHR < Tumors induce rapid blood vessel is expressed even though healthy tissue does growth to nourish themselves not show such expression = Anti-angiogenesis drugs are a mulfi-b
Slide 12: Intraperitoneal Delivery (IP) Is Another Key Advantage
Intraperitoneal Delivery (IP) Is Another Key Advantage = Most, if not all, ovarian cancer lesions remain within the peritoneal cavity and ascites = By delivering through an IP catheter, the engineered T cells will largely remain in the peritoneal cavity = Very few, if any, engineered T cells escape
Slide 13: Dose-escalation first-in-human clinical trial in ovarian cancer
Dose-escalation first-in-human clinical trial in recurrent/chemoresistant ovarian Cancer + Pl: R. Wenham, MD + LP. vs. LV.> Comparative safety and effectiveness iTable 1. Dose-escalation scheme. Dose Level Cyclophosphamide dose FSHCER T-cell Dose Number of Patients | | / 4 | 1 None 1 x 105 cells/kg
Slide 14: Clinical Results to Date
Clinical Results to Date 1. Dosage (9? patients as of March 2025) 1. First three dosage cohorts complete 2. Excellent safety profile to date 3. One patient alive over 22 months from treatment Aanixa
Slide 15: Cancer Vaccines
CANCER VACCINES 15
Slide 16: Key Aspects of Vaccines
Key Aspects of Vaccines An effective vaccine teaches the immune system to target and destroy "something bad” + Pathogen * Cells invaded or modified by pathogen * Cancer Cell Sometimes its relatively easy to teach the immune system to identify "something bad” but sometimes, its very difficult, for ex
Slide 17: Two Broad Types to Cancer Vaccines
Two Broad Types to Cancer Vaccines « Rad < 6 < + Vaccine Definition: Vaccines do not attack the cancer directly like chemotherapeutic agents. They try to teach the patient's immune system to destroy the cancer. There are two categories of vaccines for cancer * Therapeutic Vaccines- These vaccines tr
Slide 18: Preventative Cancer Vaccines Have Failed
« Ed < 6 < Preventative Cancer Vaccines Have Failed ...except for cancers driven by infectious agents. Human Papillomavirus (HPV) Hepatitis B Virus (HBV) Human papillomavirus (HPV) is a common sexually Hepatitis Bs caused by the hepatitis B vitus (HBV). Hepatitis Bisa viral infection that attacks th
Slide 19: Past Vaccine Development Strategy
« Ed < 6 < Past Vaccine Development Strategy * The primary vaccine strategy for cancer has emerged from successful strategies to develop therapeutics * Precision therapeutics target overexpressed proteins + Herceptin/Trastuzumab isan antibody that binds to HER2+ cells Normal cell HER2+ cell + But it
Slide 20: Why Have Preventative Cancer Vaccines Failed?
Why Have Preventative Cancer Vaccines Failed? Cancer vaccines typically target proteins overexpressed on tumors. Normal Cell HER2+ Cell wi a a a. hn, = = oo i % Perens Mechanisms exist to limit immune response Autoimmune disorders are created by against self-proteins. © © Proteins overexpressed on c
Slide 21: What About Mutated Proteins— Neo-antigens?
What About Mutated Proteins— Neo-antigens? Mechanisms exist to limit immune response against self-proteins. « May be Ok for therapeutic purposes * Typically requires co-administration with other immunotherapeutic agents and/or cytokines * Typically requires sequencing of individual tumors and determ
Slide 22: Retired Tissue-Specific Proteins
RETIRED TISSUE-SPECIFIC PROTEINS HYPOTHESIS A New Paradigm for Prophylactic Cancer Vaccines 22
Slide 23: Retired Tissue-Specific Proteins for Prophylactic and Therapeutic Cancer Vaccines
Retired Tissue-Specific Proteins for Prophylactic and Therapeutic Cancer Vaccines « Rad < 6 < The Right Antigen is Critical Retired tissue-specific protein definition: Why is this a good antigen for prophylactic vaccines? © Protein that is uniquely expressed, in a © Vaccination is performed at an ag
Slide 24: Vaccine Program
Vaccine Program Breast Cancer
Slide 25: Breast Cancer Vaccine: Retired Tissue-Specific Protein
Breast Cancer Vaccine: Retired Tissue-Specific Protein Exclusive worldwide license from Cleveland Clinic Retired Tissue-Speciific Protein a-LACTALBUMIN Expressed at periods of life, but no longer expressed as we = Expressed only in the breast and only during lactation age = Expressed in tumor cells,
Slide 26: Immune system will only attack cancer cells if vaccinated
« Rad < 6 < Immune system will only attack cancer cells if vaccinated by our vaccine Will kill two Vaccinated types of cells patient's Immune system Cells Enabling Lactation * If patient is not lactating, the immune system will only target the pathogenic cancer cells and nothing else in the body. *
Slide 27: Proof of Concept - Published in 2012
Aanixa Proof of Concept” -Published in 2012 LITTER Vaccinated mouse (9) After vaccination, mice were mated and allowed to have a litter. © the pups were perfectly normal at birth. © Mothers were unable to produce milk. This proves that vaccination targeting a-lactalbumin enables the immune system to
Slide 28: Pre-Clinical Studies: Vaccination Prevents Breast Cancer
Pre-Clinical Studies: Vaccination Prevents Breast Cancer Aanixa Well-Tolerated Robust Pre-Clinical Response MMTV-neu Mice e 8 8.8 g 8 Tumor Size (mm?) 8 8 _ Vaccinated Controls 100% of a-LACTALBUMIN A 80% of un-vaccinated mice vaccinated mice did not develop roast cancer developed breast cancer Vacc
Slide 29: Phase 1 Trial
Phase 1 Trial Conducted by Cleveland Clinic, funded by U.S. Department of Defense (DOD) An open-label Phase 1 dose-escalation trial Phase 1b Phase 1c (in pr 5) (in pre + Healthy women w/mutations * Chosen to undergo artislscintovul + 24-36 Patients who have prophylactic mastectomy 0 Aenea receive th
Slide 30: Positive Clinical Results patients dosed through November 2024
Positive Clinical Results 26 patients dosed through November 2024 © TNBC patients who have undergone standard of care, but are at risk of recurrence (40-80% recur in 5 years)— cohort 1 © Genetic risk patients choosing prophylactic mastectomies— cohort 2 © Patients with residual disease taking Keytru
Slide 31: Additional Thoughts Regarding Retired Proteins
Additional Thoughts Regarding Retired Proteins * How do we know if alpha-lac is not expressed somewhere in a vaccinated woman's body at some other stage in life, thus causing autoimmunity? + We don't know for sure, although we don't think so based on the function of the protein * There is no practic
Slide 32: Phase 2 Breast Cancer Vaccine Trial
Phase 2 Breast Cancer Vaccine Trial « Rad < 6 < Near Term- Therapeutic Approach Phase 2 trial in neo-adjuvant setting - before surgery + Faster evaluation of efficacy + Multiple types of Breast Cancer + Faster data, enabling earlier alliance with big Pharma Two Arms + Standard of Care + Vaccine * St
Slide 33: Breast Cancer Vaccine Development Plan and Market Opportunity
Breast Cancer Vaccine Development Plan and Market Opportunity Aanixa inches will occur in stages Neo-Adjuvant Therapeutic treatment Market Opportunity * 2023- $38.35 billion! * 2030- $89.67 billion, projected CAGR of 12.9%! Adjuvant-therapeutic treatment Market Opportunity + Over 3.8 MM breast cance
Slide 34: Fox News Video
Fox News Video Aanixa 34
Slide 35: Pre-Clinical Pipeline
Pre-Clinical Pipeline Ovarian, Lung, Prostate, Colon
Slide 36: Collaboration with Cleveland Clinic and the National Cancer Institute
Collaboration with Cleveland Clinic and the National Cancer institute Driven by current promising data form Breast Cancer Vaccine Clinical Trial Aanixa Maintain our Lead in Prophylactic Cancer Vaccine Development Development of Additional Cancer Vaccines = Bioinformatic analysis utilizing advanced A
Slide 37: Anixa Snapshot
Anixa Snapshot Clinical-stage company developing first-in-class products to treat & prevent cancer Robust Pipeline $$$ Strong Balance Sheet lal Strong Clinical Data all Clean Capital Table Aanixa we fa ES ©) Key Significant TAM Partnerships Opportunity Strong Consistent Capital Efficient Insider Buy
Slide 38: Contact Information
Aanixa BIOSCIENCES CONTACT INFORMATION: Amit Kumar, Ph.D. Chairman & CEO. ak@anixa.com Mike Catelani President, COO & CFO. meatelani@anixa.com NASDAQ:ANIX